l

Low psa metastatic prostate cancer

Biochemical prostate cancer recurrence post surgery/rt

In general, the sooner a man is diagnosed with prostate cancer, the more likely he is to undergo effective care and stay disease-free. Prostate cancer has one of the highest overall prognoses of any cancer.
It’s important to remember that survival rates and the probability of recurrence are based on averages and do not represent the outcome of any given patient. Many factors affect the prognosis of prostate cancer. Based on your particular condition, your doctor will have insight and advice.
Prostate cancer is found in the local or regional stages, which include stages I, II, and III, in about 80% to 85% of cases. After five years, many men who were diagnosed and treated locally or regionally would be disease-free.
Prostate cancers diagnosed at a later stage have a five-year survival rate of just 28%, which is significantly lower than local and regional prostate cancers. Stage IV prostate cancers that have metastasized (spread) to lymph nodes, lungs, or bones in other areas of the body are included in this overall survival rate.

Stampede: local radiotherapy improves survival in

The clinical and pathological characteristics of metastatic prostate cancer with normal serum prostate-specific antigen (PSA) levels were investigated. At the time of diagnosis, four patients with metastatic prostate cancer had serum PSA levels that were beyond the normal range. Many of the tumors were adenocarcinomas with low differentiation. In all of the patients, endocrine therapy was used as the first line of treatment. Despite surgery, all of the patients died of prostate cancer at 2, 8, 9, and 38 months. Three of four patients had elevated serum markers including carcinoembryonic antigen (CEA), CA19-9, CA15-3, CA125, neuron-specific enolase, and pro-gastrin releasing peptide as the disease progressed. The initial biopsy specimens were found to be positive for CEA and chromogranin A in 4 and 3 cases, respectively, according to immunohistochemistry. Such markers can help with disease follow-up in advanced prostate cancer patients with low PSA levels.
Furuya, Y.
Permissions and privileges
Permissions and Reprints
In relation to this article
This article can be cited.
R. Nishio, Y. Furuya, O. Nagakawa, and others Prostate cancer that has spread and has a typical amount of prostate-specific antigen in the blood.

Case 1: the importance of psa doubling time in prostate

Rabin Medical Center, Beilinson Campus, Petah Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, Genitourinary Medical Oncology Unit and Department of aOncology, bPathology, and cUrology
Drug Dosage: The writers and publisher have gone to considerable lengths to ensure that the drug collection and dosage procedures outlined in this text are existing guidelines and practice at the time of publication. However, the reader is advised to review the package insert for each prescription for any changes in indications and dosage, as well as any additional alerts and precautions, in light of ongoing studies, changes in government legislation, and the continuous flow of information relating to drug therapy and drug reactions. When the recommended agent is a new and/or infrequently used medication, this is especially important.
Disclaimer: The claims, views, and data in this publication are solely the responsibility of the individual writers and contributors, not the publishers or editor (s). The inclusion of advertising or product references in the publication does not mean a guarantee, endorsement, or approval of the advertised goods or services, or of their efficacy, quality, or protection. Any harm to persons or property arising from any ideas, processes, directions, or items referred to in the material or advertising is not the responsibility of the publisher or editor(s).

Psa relapse after surgery or radiation | prostate cancer

a summary

Understanding the value of psa testing for prostate cancer

The goal was to see how many men had metastatic prostate cancer in various groups based on T stage, Gleason Grade Group (GGG), and serum levels of prostate-specific antigen (PSA), and whether PSA could be used to rule out metastatic prostate cancer when combined with T stage and GGG. In Prostate Cancer Data Base Sweden 4.0, we found 102,076 men who were diagnosed with prostate cancer between 2006 and 2016. PSA metastasis risk was calculated based on T stage and a five-tiered GGG. We used multiple imputation to identify metastatic prostate cancer in men who had not undergone bone imaging. Bone metastases were linked to advanced T level, high GGG, and high PSA. Just 79/38 190 (0.2%) of men with T1-2 and GGG 1 had PSA above 500 ng/mL, and 29/79 (44%) of these men had metastases, while 1 154/7 018 (16%) of men with T3-4 and GGG 5 had PSA above 500 ng/mL, and 1 088/1 154 (94%) of these men had metastases. However, no PSA cut-off could reliably distinguish the majority of men with metastatic prostate cancer (i.e. high sensitivity) while still correctly classifying the majority of men who did not have metastasis (i.e. low sensitivity) (i.e. high specificity). In conclusion, these findings support the use of imaging to confirm bone metastases in men with advanced prostate cancer, as no PSA level in combination with T stage and GGG could reliably rule in metastatic prostate cancer, allowing bone imaging to be avoided safely.